Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon May 07, 2024 5:09pm
153 Views
Post# 36027589

Yet another day gone by, very little if anything

Yet another day gone by, very little if anything So today, Tuesday. Not much happening.
Yet again, as I mentioned this am, there continues to be end of day support for the price.
Agreed, the volume & price movements quite insignificant.
What is interesting is the activity itself.
irinically bucky claims to be realistic?
A quick search of his posts....
zero, absolutely zero content of any value.
So far all he has materialized is random insults, none sense or put downs, either of other posters, or Onc itself.
Again, with zero substance.
Akin of grade school name calling.
Just a mindless, childish, eneducated troll.
Obviously desperatly trying to recover his short position.
bucky!want to gain some credibility?
comment, with some knowledge on the various trials?
I know you have a short memory & obviously can't read well, so a brief summary just for you.
1. Onc recently applied to FDA, to seek guidance & approval of the Aware-1, biomarkers, to be included in the phase 3 for MBc. Allowing such, will speed the phase 3 triall & allow Onc to pre- select participants thst are shown to react to Pela. The biomarkers can be detected within a simple blood test, after 2 weeks. ...existing chemo trials sometime require 6 weeks & various scans, to find out if the chemo is working or not.
Giving Pelareorep a huge comercial & clinical advantage.
2. They are waiting ..still for " events" aks deaths if mbc patients. To finalize the overall survival. Hard to grasp for those in a rush. Longer for O.S. Is better.
3. oncolytics biotech has two abstract presentations coming up next month.They would not be presenting bad news.
4.they were granted $500,000 towards an additional arm under the pancreatic cancer co- therapy.
I could go on.
All factual peer reviewed information.
actually every single update over the past 6 months has shown positive progress.
tomorrow yet another day.
regards


<< Previous
Bullboard Posts
Next >>